Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Soleno Therapeutics Inc SLNO

Healthcare Biotechnology
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3... see more

Recent & Breaking News (NDAQ:SLNO)

Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

GlobeNewswire September 27, 2023

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

GlobeNewswire September 26, 2023

Soleno Therapeutics to Present at the Cantor Global Healthcare Conference

GlobeNewswire September 25, 2023

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

GlobeNewswire August 16, 2023

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 8, 2023

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 9, 2023

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

GlobeNewswire May 3, 2023

Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days

GlobeNewswire March 28, 2023

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

GlobeNewswire March 21, 2023

Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 7, 2023

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

GlobeNewswire January 26, 2023

Soleno Therapeutics Announces Financing Commitment for up to $60 Million

GlobeNewswire December 19, 2022

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 9, 2022

Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

GlobeNewswire October 3, 2022

Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 10, 2022

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

GlobeNewswire July 20, 2022

Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference

GlobeNewswire July 11, 2022

Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS

GlobeNewswire June 13, 2022

Soleno Therapeutics Announces Presentations at ENDO 2022

GlobeNewswire June 7, 2022